Adrenal Cancer

Adrenal cancer, specifically adrenocortical cancer, is a rare and highly aggressive malignancy of the adrenal cortex with an annual incidence of 1–2 per million and a poor 5-year survival rate of 25%. It may present as functional or non-functional tumors, with functional variants causing symptoms due to hormone excess. Surgical resection remains the primary curative treatment, and certain inherited syndromes are associated with increased risk.
References:

  • Adrenal Cancer (2)

By Targets:
By Categories:
By Clinical Status:
Adrenal Cancer
Clear Filters
FHD-609
FHD-609
0 Images
Cat. No.: HY-153367
CAS No.: 2676211-64-4
Purity: 98.95%
  • Formula: C47H56N8O6
  • Molecular Weight: 829.00

FHD-609 is a BRD9 PROTAC degrader. FHD-609 induces BRD9 degradation, downregulates primary transcripts of HBG/HBD, Myc expression and proliferation gene sets, reduces the levels of synovial sarcoma tumor proliferation markers, and inhibits tumor growth. FHD-609 can be used in research related to advanced synovial sarcoma, SMARCB1-deficient tumors and adrenocortical carcinoma.

loading...
    loading...
View All Sizes
Boxidine
Boxidine
0 Images
Cat. No.: HY-W726633
CAS No.: 10355-14-3
  • Formula: C19H20F3NO
  • Molecular Weight: 335.37

Boxidine is an orally active DHCR7 inhibitor. Boxidine inhibits DHCR7, blocks the conversion of 7-Dehydrocholesterol (HY-113279) to Cholesterol (HY-N0322), reduces serum cholesterol levels, causes accumulation of 7-dehydrocholesterol in serum and tissues, and inhibits sterol absorption. Boxidine exhibits antiproliferative and anticancer activities, with marginal activity against mouse tumors. Boxidine can be used in research related to diseases such as tumors and adrenal cancer.

loading...
    loading...
View All Sizes
Assay Types